Candel Therapeutics to Showcase Pipeline at Canaccord Growth Conference
Event summary
- Candel Therapeutics will present at Canaccord Genuity’s 46th Annual Growth Conference on August 12, 2026.
- The presentation will be webcast live and archived for 90 days post-event.
- Aglatimagene besadenovec is Candel's lead product candidate with multiple FDA designations.
- Linoserpaturev is in phase 1b trials for recurrent high-grade glioma.
The big picture
Candel Therapeutics is positioning itself as a key player in multimodal immunotherapies, with a focus on solid tumors. The company's presentation at Canaccord Genuity’s Growth Conference comes amid increasing competition in the oncology space and growing investor interest in innovative cancer treatments. Candel's ability to secure multiple FDA designations highlights its strategic advantage in navigating regulatory hurdles.
What we're watching
- Clinical Progress
- How the phase 1b trial results for linoserpaturev will impact its regulatory path.
- Regulatory Strategy
- Whether Candel can leverage its multiple FDA designations to accelerate approval timelines.
- Market Positioning
- The pace at which Candel can differentiate itself in the competitive oncology immunotherapy space.
Related topics